Depending on the pre-ablation immune status of the client in autologous HSCT or on the immune status of the donor in allogeneic HSCT, there may be some immunity to vaccine preventable diseases following transplantation. However, antibody levels to vaccine preventable diseases decline 1-4 years after HSCT if the recipient is not re-immunized, regardless of whether the transplant was autologous or allogeneic.